<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Flaker, Greg C.</style></author><author><style face="normal" font="default" size="100%">Barbera, Saverio J.</style></author><author><style face="normal" font="default" size="100%">Jung, Werner</style></author><author><style face="normal" font="default" size="100%">Lip, Gregory Y. H.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">OACs in Complex Settings</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-07-02 10:57:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-21</style></pages><abstract><style  face="normal" font="default" size="100%">The safety and efficacy of oral anticoagulation with warfarin or the nonwarfarin oral anticoagulants have not been well established in settings such as cardioversion or ablation for atrial fibrillation, coronary artery disease, percutaneous coronary intervention, and stent placement. Recent meta-analyses and randomized trials provide new data to consider regarding the positioning of oral anticoagulation in these settings.</style></abstract><number><style face="normal" font="default" size="100%">12</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>